Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

  • Technology appraisal guidance
  • TA118
  • Published: 
  • Last updated: 
Download guidance (PDF)

Appendix B. Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by School of Health and Related Research (ScHARR), The University of Sheffield:

I) Tappenden P, Jones R, Paisley S, Carroll C. The use of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer, 21 February 2006.

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope, assessment report and the appraisal consultation document (ACD). Consultee organisations are provided with the opportunity to appeal against the final appraisal determination.

II) Manufacturers/sponsors:

  • Roche Products (bevacizumab)

  • Merck Pharmaceuticals (cetuximab)

III) Professional/specialist and patient/carer groups:

  • Association of Cancer Physicians

  • Association of Coloproctologists of Great Britain

  • British Oncological Association

  • British Oncology Pharmacy Association (BOPA)

  • British Psychosocial Oncology Society (BPOS)

  • Cancer Research UK

  • Royal College of General Practitioners

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians' Medical Oncology Joint Special Committee

  • Royal College of Radiologists

  • Royal College of Surgeons

  • Royal Pharmaceutical Society

  • Beating Bowel Cancer

  • Cancer Voices

  • Cancerbackup

  • Bowel Cancer UK (Colon Cancer Concern)

  • CORE (Digestive Disorders Foundation)

  • Long-term Medical Conditions Alliance

  • Lynn's Bowel Cancer Campaign

  • Macmillan Cancer Relief

  • Marie Curie Cancer Care

  • National Cancer Alliance

  • National Council for Palliative Care

  • Teenage Cancer Trust

  • Tenovus Cancer Information Centre

  • Department of Health

  • East Hampshire Primary Care Trust

  • East Leeds Primary Care Trust

  • Welsh Assembly Government

IV) Commentator organisations (without the right of appeal):

  • Board of Community Health Councils in Wales

  • British National Formulary

  • National Public Health Service for Wales

  • NHS Confederation

  • NHS Purchasing and Supplies Agency

  • NHS Quality Improvement Scotland

  • Sanofi-Aventis (oxaliplatin)

  • Pfizer (irinotecan)

  • Roche Products (capecitabine)

  • Bristol-Myers Squibb Pharmaceuticals (tegafur uracil)

  • Mayne Pharma (fluorouracil)

  • Medac UK (fluorouracil)

  • Wyeth Pharmaceuticals (calcium levofolinate)

  • Institute of Cancer Research

  • MRC Clinical Trials Unit

  • National Cancer Research Institute

  • National Cancer Research Network

  • National Coordinating Centre for Health Technology Assessment

  • School of Health & Related Research Sheffield

  • National Collaborating Centre for Cancer

B. The following individuals were selected from clinical expert and patient advocate nominations from the professional/specialist and patient/carer groups. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on bevacizumab and cetuximab for metastatic colorectal cancer by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Alan Anthoney, Senior Lecturer and Honorary Consultant in Medical Oncology, Cookridge Hospital (clinical expert)

  • Dr David Smith, Consultant Medical Oncologist, Association of Cancer Physicians (clinical expert)

  • Dr Edward Levine, Consultant Clinical Oncologist, Association of Coloproctology (clinical expert)

  • Mr Leonard Rhys Evans, Senior Lecturer, Harrow Business School (patient expert)

  • Ms Caroline Cleary, Pharmacist, Payden's (patient expert)